Minervini Andrea, Rosaria Raspollini Maria, Tuccio Agostino, Di Cristofano Claudio, Siena Giampaolo, Salvi Matteo, Vittori Gianni, Sebastianelli Arcangelo, Lapini Alberto, Serni Sergio, Carini Marco
Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Department of Pathology, University of Florence, Careggi Hospital, Florence, Italy.
Urol Oncol. 2014 Jan;32(1):50.e15-22. doi: 10.1016/j.urolonc.2013.07.018. Epub 2013 Nov 13.
To evaluate the pathological characteristics of peritumoral capsule (PC) and the prognostic effect of capsule penetration on tumor recurrence in patients treated with tumor enucleation for clinically intracapsular renal cell carcinomas (RCCs).
PC status was analyzed in 304 consecutive patients with single intracapsular RCC. Degree and side of capsule penetration if present were evaluated. Mean (median, range) follow-up was 49 months (46, 25-69). Local recurrence rate, progression-free survival (PFS), and cancer-specific survival were the main outcomes. Statistical analyses included the Kaplan-Meier method, log-rank test, and univariate and multivariate Cox regression models.
Overall, 51% of RCCs had intact PC and free from neoplastic invasion (PC-), 34.9% had capsular penetration on the parenchymal side (PCK), and 14.1% had tumor invasion on the perirenal fat tissue side (PCF). None of the patients had positive surgical margins. The 5-year PFS rates for tumors PC-, PCK, and PCF were 97.5%, 96.7%, and 77.1%, respectively (P<0.0001). The multivariate Cox model showed PCF to be the sole significant independent predictor of PFS, whereas patients who had PCK did not present a significant increased risk in developing recurrence.
Tumor enucleation is an oncologically safe nephron-sparing surgery technique. PCF is a significant and independent predictor of tumor recurrence in patients with clinically intracapsular RCCs scheduled for nephron-sparing surgery. PCK does not predict the risk of recurrence.
评估临床包膜内肾细胞癌(RCC)行肿瘤剜除术患者的瘤周包膜(PC)病理特征及包膜穿透对肿瘤复发的预后影响。
分析304例连续性单发性包膜内RCC患者的PC状况。评估包膜穿透的程度及部位(若存在)。平均(中位数,范围)随访时间为49个月(46,25 - 69)。主要观察指标为局部复发率、无进展生存期(PFS)和癌症特异性生存期。统计分析包括Kaplan-Meier法、对数秩检验以及单因素和多因素Cox回归模型。
总体而言,51%的RCC包膜完整且无肿瘤侵犯(PC-),34.9%在实质侧有包膜穿透(PCK),14.1%在肾周脂肪组织侧有肿瘤侵犯(PCF)。所有患者手术切缘均为阴性。PC-、PCK和PCF肿瘤的5年PFS率分别为97.5%、96.7%和77.1%(P<0.0001)。多因素Cox模型显示PCF是PFS的唯一显著独立预测因素,而有PCK的患者复发风险未显著增加。
肿瘤剜除术是一种肿瘤学上安全的保留肾单位手术技术。PCF是计划行保留肾单位手术的临床包膜内RCC患者肿瘤复发的显著且独立预测因素。PCK不能预测复发风险。